SRSF5 and neoplasm: Mechanistically, LINC01852 binds serine/arginine rich splicing factor 5 (SRSF5) and promotes its degradation and suppresses SRSF5-mediated alternative splicing of PKM2, thereby inhibiting aerobic glycolysis, tumor growth and chemoresistance.